Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.

Cancer research - 1 May 2009

Kurosu Tetsuya, Ohki Manabu, Wu Nan, Kagechika Hiroyuki, Miura Osamu

Abstract excerpt

Although the BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia, relapse with emerging imatinib resistance mutations in the BCR/ABL kinase domain poses a significant p...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Benzopyrans
Share to Biphenyl Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Boronic Acids

Share to Bortezomib

Share to Interleukin-3

Share to Nitrophenols

Share to Sorafenib

Source

Identifiers

PMID: 19366808
DOI: 10.1158/0008-5472.CAN-08-2978

Genes

BCR
BOC

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19366808-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.PMID 19366808Read ↗

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.Semantic proximity Read ↗

Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1)Semantic proximity Read ↗

Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemiaSemantic proximity Read ↗

Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance.Semantic proximity Read ↗

Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.Semantic proximity Read ↗

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.Semantic proximity Read ↗

Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in <i>FLT3-</i> and <i>KIT-</i> Mutant AMLSemantic proximity Read ↗

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro , Ex Vivo , and In Vivo in the 5T33MM Mouse ModelSemantic proximity Read ↗

Bortezomib induces cell apoptosis and increases the efficacy of αPD-1 in BCR::ABL T315I mutation CML by targeting UBE2Q1.Semantic proximity Read ↗

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells.Semantic proximity Read ↗

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML CellsSemantic proximity Read ↗

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.